Lineage Cell Therapeutics Inc. Common Stock (LCTX)

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

72

Website

lineagecell.com/

Fundamentals

1-day range

$1.11$1.18

Market cap

$276.72M

P/E (trailing)

—

P/E (forward)

-10.88

EPS (trailing)

$-0.14

Dividend yield

—

Beta

1.55

Avg. volume

1.35M

Forecasts

6 analyst ratings

Lineage Cell Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• LCTX

  Lineage Cell Therapeutics Inc. Common Stock

  $1.11

  ▼ 4.31%
  Market cap $276.72MP/E —
  $1$2.09
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $273.38MP/E —
  $2.26$10.4
• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $289.80MP/E 26.94
  $1.85$5.15
• EDIT

  Editas Medicine Inc. Common Stock

  $3.15

  ▼ 4.55%
  Market cap $259.45MP/E —
  $1.66$4.54
• SRZN

  Surrozen Inc. Common Stock

  $22.42

  ▼ 6.62%
  Market cap $252.87MP/E —
  $10.73$35
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• TARA

  Protara Therapeutics Inc. Common Stock

  $3.82

  ▼ 4.26%
  Market cap $223.13MP/E —
  $3.02$7.82

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
  Yahoo · 8/14/2026
• Lineage Cell Therapeutics Q2 Earnings Call Highlights
  Yahoo · 8/9/2026
• Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/7/2026
• Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
  Yahoo · 8/7/2026
• Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances
  ChartMill · 8/6/2026
• Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
  Yahoo · 8/6/2026
• Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
  Yahoo · 8/6/2026

• Amin Dipti · July 1, 2026 · Grant

  125.0K
• Anula Jayasuriya · July 1, 2026 · Grant

  125.0K
• Russell Angus C. · July 1, 2026 · Grant

  125.0K
• Michael H. Mulroy · July 1, 2026 · Grant

  125.0K
• Deborah J. Andrews · July 1, 2026 · Grant

  125.0K
• Bradsher Neal C · July 1, 2026 · Grant

  125.0K
• Brian M. Culley · March 12, 2026 · Buy

  15.0K @ $1.63
• Jill Ann Howe · March 5, 2026 · Grant

  1.05M
• George A. Samuel III · March 5, 2026 · Grant

  900.0K
• Brian M. Culley · March 5, 2026 · Grant

  3.25M

Institutional Ownership

March 31, 2026

Total shares held

110.37M

Total value held

$173.57M

Institutional holders

126